SEC Form 4 · accession 0001365618-16-000009

Anacor Pharmaceuticals, Inc. · ANAC

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Table I — non-derivative securities

Table II — derivative securities

Explanation of responses

• F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Venrock Healthcare Capital Partners, L.P. ("VHCP"), VHCP Co-Investment Holdings, LLC ("VHCP Co-Invest"), Venrock Healthcare Capital Partners II, L.P. ("VHCP2"), VHCP Co-Investment Holdings II, LLC ("VHCP Co-Invest2"), Venrock Associates IV, L.P. ("VA4"), Venrock Partners, L.P. ("VP") and Venrock Entreprenerus Fund IV, L.P. ("VEF4") on March 16, 2016.
• F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.04 to $101.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) - (7) to this Form 4.
• F3The shares are held as follows: 34,207 shares held by VA4, 6,976 shares held by VP, 840 shares held by VEF4, 77,333 shares held by VHCP, 14,143 shares held by VHCP Co-Invest, 116,675 shares held by VHCP2 and 22,076 shares held by VHCP Co-Invest2.
• F4Venrock Management IV, LLC ("VM4"), Venrock Partners Management, LLC ("VPM") and VEF Management IV, LLC ("VEFM4") are the sole general partners of VA4, VP and VEF4, respectively, and may be deemed to beneficially own these shares. VHCP Management, LLC ("VHCP Management") is the general partner of VHCP and the manager of VHCP Co-Invest and may be deemed to beneficially own these shares. VHCP Management II, LLC ("VHCP Management 2") is the general partner of VHCP2 and the manager of VHCP Co-Invest2 and may be deemed to beneficially own these shares. Anders Hove is a member of VM4, VPM and VEFM4 and a managing member of VHCP Management and VHCP Management 2. Dr. Hove expressly disclaims beneficial ownership over all shares held by VA4, VP, VEF4, VHCP, VHCP Co-Invest, VHCP2, VHCP Co-Invest2, VM4, VPM, VEFM4, VHCP Management and VHCP Management 2 except to the extent of his indirect pecuniary interest therein.
• F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.01 to $100.00, inclusive.
• F6The shares are held as follows: 9,095 shares held by VA4, 1,855 shares held by VP, 223 shares held by VEF4, 20,561 shares held by VHCP, 3,761 shares held by VHCP Co-Invest, 31,021 shares held by VHCP2 and 5,869 shares held by VHCP Co-Invest2.
• F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.85 to $99.00, inclusive.
• F8The reporting person is a member of VR Management, LLC (the "Management Company"). Under an agreement between the reporting person and the Management Company, the reporting person is deemed to hold an aggregate of 794 of the reported securities for the sole benefit of the Management Company (the "Management Company Shares"). The Management Company may be deemed the indirect beneficial owner of the Management Company Shares, and the reporting person may be deemed the indirect beneficial owner of the Management Company Shares through his interest in the Management Company. The reporting person disclaims beneficial ownership of the Management Company Shares except to the extent of his indirect pecuniary interest therein.